Evaluation of Real-World Studies on Management of Relapsed Multiple Myeloma After BCMA-Directed Therapy Failure from U.S. Academic Centers and USMIRC

Nagham Youssef; Maha Hameed; Shebli Atrash; Barry Paul; Abdullah Mohammad Khan; Hira Shaikh; Christopher Strouse; Andrew Vegel; Zena Chahine; Anita Mazloom; Muhammad Salman Faisal; Taha Al-Juhaishi; Omar Alkharabsheh; Anas Zayad; Carmel Awadallah; Jordan Snyder; Zahra Mahmoudjafari; Muhammad Umair Mushtaq; Jeries Kort; Alma Habib; Forat Lutfi; Al-Ola Abdallah; Mansi Shah; Prerna Mewawalla; Sarah Waheed

doi:10.3390/curroncol33060355

Back

Evaluation of Real-World Studies on Management of Relapsed Multiple Myeloma After BCMA-Directed Therapy Failure from U.S. Academic Centers and USMIRC

Journal article

Open access

Peer reviewed

Evaluation of Real-World Studies on Management of Relapsed Multiple Myeloma After BCMA-Directed Therapy Failure from U.S. Academic Centers and USMIRC

Nagham Youssef, Maha Hameed, Shebli Atrash, Barry Paul, Abdullah Mohammad Khan, Hira Shaikh, Christopher Strouse, Andrew Vegel, Zena Chahine, Anita Mazloom, …

Current oncology (Toronto), Vol.33(6), 355

06/12/2026

DOI: 10.3390/curroncol33060355

PMID: 42346255

Files and links (1)

url

https://doi.org/10.3390/curroncol33060355View

Published (Version of record) Open Access

Abstract

B-cell maturation antigen (BCMA)-directed therapies (BDTs) have transformed relapsed/refractory multiple myeloma treatment, but optimal post-failure sequencing remains undefined. We evaluated real-world outcomes from three retrospective, multicenter analyses. Study 1 compared BCMA CAR-T and BCMA T-cell engagers (TCEs) in BDT-exposed patients (n = 95). Study 2 evaluated teclistamab in BDT-exposed versus BDT-naïve patients (n = 164). Study 3 examined talquetamab (GPRC5D-targeting TCE) in heavily pretreated patients (n = 68). CAR-T therapy achieved superior outcomes versus TCE (overall response rate [ORR] 79% vs. 51%, p < 0.001; median overall survival [OS] 30 vs. 12 months, p = 0.008). Teclistamab-treated BDT-exposed patients had lower ORR (53% vs. 68%, p = 0.02) and shorter median progression-free survival (PFS; 2.5 vs. 9.7 months, p = 0.01) compared with BDT-naïve patients. Administration < 6 months post-BDT showed inferior outcomes (hazard ratio [HR] 2.5 for PFS; HR 2.9 for OS). Talquetamab achieved an ORR of 68.3% among BDT-exposed patients, with significantly lower response rates when administered < 6 months post-BDT or when BDT was the immediate preceding treatment (56.8% vs. 84.6% and 48% vs. 80.6%, respectively). Treatment-free intervals of ≥6 months between T-cell-redirecting therapies improved efficacy and survival. Post-BDT sequencing should prioritize CAR-T therapy when feasible, allow >6-month intervals before BDT re-challenge, and utilize non-BCMA targets for early relapse or BDT-refractory disease.

United States

Aged

B-Cell Maturation Antigen - immunology

Female

Humans

Immunotherapy, Adoptive - methods

Male

Middle Aged

Multiple Myeloma - drug therapy

Multiple Myeloma - therapy

Neoplasm Recurrence, Local

Retrospective Studies

Details

Title: Subtitle: Evaluation of Real-World Studies on Management of Relapsed Multiple Myeloma After BCMA-Directed Therapy Failure from U.S. Academic Centers and USMIRC
Creators: Nagham Youssef - Levine Cancer Institute
Maha Hameed - Florida State University
Shebli Atrash - Levine Cancer Institute
Barry Paul - Levine Cancer Institute
Abdullah Mohammad Khan - The Ohio State University
Hira Shaikh - University of Iowa
Christopher Strouse - University of Iowa
Andrew Vegel - University of Iowa
Zena Chahine - University of Kentucky
Anita Mazloom - USA Mitchell Cancer Institute
Muhammad Salman Faisal - University of Oklahoma Health Sciences Center
Taha Al-Juhaishi - University of Oklahoma Health Sciences Center
Omar Alkharabsheh - University of Cincinnati
Anas Zayad - Hamad Medical Corporation
Carmel Awadallah - Rockaway Waterfront Alliance
Jordan Snyder - University of Kansas Medical Center
Zahra Mahmoudjafari - University of Kansas Medical Center
Muhammad Umair Mushtaq - University of Kansas Medical Center
Jeries Kort - University of Kansas Medical Center
Alma Habib - University of Kansas Medical Center
Forat Lutfi - University of Kansas Medical Center
Al-Ola Abdallah - University of Kansas Medical Center
Mansi Shah - Rutgers, The State University of New Jersey
Prerna Mewawalla - Allegheny Health Network
Sarah Waheed - Johns Hopkins Hospital
Resource Type: Journal article
Publication Details: Current oncology (Toronto), Vol.33(6), 355
DOI: 10.3390/curroncol33060355
PMID: 42346255
NLM abbreviation: Curr Oncol
ISSN: 1718-7729
eISSN: 1718-7729
Publisher: MDPI; BASEL
Grant note: This research received no external funding.
Language: English
Date published: 06/12/2026
Academic Unit: Hematology, Oncology, and Blood & Marrow Transplantation; Internal Medicine
Record Identifier: 9985176653402771

Metrics

1 Record Views